Plain-English translation of NCT06995625 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial (Phase 1) testing a new treatment called , which is made from special cells found in umbilical cord tissue. Researchers want to see if this medication is safe and whether it might help people recover better after a stroke. The treatment is given as injections into the bloodstream over 5 days.
Currently, treatment options for stroke are limited, especially for people who don't respond well to standard clot-busting therapies or mechanical procedures. This medication is being studied because laboratory research suggests that stem cell-derived substances may help the brain heal and reduce stroke damage.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive daily intravenous injections of the medication for 5 consecutive days. The trial is small (18 people total across three groups), and doctors will closely monitor your safety and how well you recover from your stroke. You will need to complete follow-up visits and tests so researchers can track your progress and watch for any side effects.
AI-generated summary from trial data · Aug 12, 2026 · Not medical advice
South Korea
Phase
Safety & dosing
Sponsor
S&Ebio Co. Ltd.
Enrollment target
~18 participants
Started
June 2026
Primary completion
March 2027
Age range
19 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Oh Young Bang, MD, Ph.D
S&Ebio Co. Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.